ClinicalTrials.gg
CompletedNCT03879863Updated Jan 23, 2025Results posted

The RENEW Trial: A Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Subjects With Dry Eye Disease

A Phase 3 interventional study of Reproxalap Ophthalmic Solution (0.25%) QID and Vehicle Ophthalmic Solution QID in Dry Eye, sponsored by Aldeyra Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-23.

Sponsored by Aldeyra Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
422
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc. — none open to participants now, none under way, none of them phase 3. Dry Eye Syndromes · Aldeyra Therapeutics, Inc..

Enrollment
2nd of 13
422 · median 206
Started
2019
with 1 other
Phase 3
6 of 13
none open now
Registered
3rd of 13
by date

Among the 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc., this one is the 2nd largest by enrollment, is one of 2 that started in 2019, is one of 6 in phase 3, and was the 3rd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

None of the 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc. is open now. The open studies under Dry Eye Syndromes, anywhere →

Where they have run

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Dry Eye Syndromes by Aldeyra Therapeutics, Inc. as a file.
02

Study summary

The RENEW Trial is a Multi-Center, Randomized, Double-Masked, Parallel-Group, Vehicle-Controlled, Adaptive Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap 0.25% Ophthalmic Solution Compared to Vehicle in Subjects with Dry Eye Disease

03

Conditions studied

  • Dry Eye

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be at least 18 years of age of either gender and any race;
  • Have a reported history of dry eye for at least 6 months prior to Visit 1;
  • Have a history of use or desire to use eye drops for dry eye symptoms within 6 months of Visit 1

Exclusion criteria

Exclusion Criteria:

  • Have any slit-lamp findings at Visit 1, including active blepharitis; meibomian gland dysfunction (MGD); lid margin inflammation; or active ocular allergies that require therapeutic treatment, or, in the opinion of the investigator may interfere with the assessment of the safety or efficacy of reproxalap or vehicle;
  • Have or be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal) or active ocular inflammation at Visit 1;
  • Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses during the study;
  • Have used any eye drops within 2 hours of Visit 1;
  • Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the last 12 months;
  • Have used ophthalmic cyclosporine or lifitegrast 5.0% ophthalmic solution within 90 days of Visit 1;
  • Have any planned ocular and/or lid surgeries over the study period or any ocular surgery within 6 months of Visit 1;
  • Have used temporary or permanent punctal plugs within 30 days prior to Visit 1 or anticipate their use during the study period
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
422 participants (actual)

Study arms

  • Experimental
    Reproxalap Ophthalmic Solution (0.25%) QID

    Drug: Reproxalap Ophthalmic Solution (0.25%) QID

  • Placebo comparator
    Vehicle Ophthalmic Solution QID

    Drug: Vehicle Ophthalmic Solution QID

  • Experimental
    Reproxalap Ophthalmic Solution (0.25%) QID to BID

    Drug: Reproxalap Ophthalmic Solution (0.25%) QID to BID

  • Placebo comparator
    Vehicle Ophthalmic Solution QID to BID

    Drug: Vehicle Ophthalmic Solution QID to BID

Interventions

  • DrugReproxalap Ophthalmic Solution (0.25%) QID

    Reproxalap Ophthalmic Solution (0.25%) administered QID for twelve weeks

  • DrugVehicle Ophthalmic Solution QID

    Vehicle Ophthalmic Solution administered QID for twelve weeks

  • DrugReproxalap Ophthalmic Solution (0.25%) QID to BID

    Reproxalap Ophthalmic Solution (0.25%) administered QID for four weeks, followed by BID administration for eight weeks

  • DrugVehicle Ophthalmic Solution QID to BID

    Vehicle Ophthalmic Solution administered QID for four weeks, followed by BID administration for eight weeks

06

What researchers measure

Primary outcomes

  1. Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS))

    Change from baseline comparison of reproxalap to vehicle for subject-reported ocular dryness score VAS (0 = no discomfort - 100 = maximal discomfort), where a higher score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline calculated using baseline score, treatment arm, visit, and the interaction of treatment arm and visit as fixed effects.

    Time frame: The efficacy assessment period (Day 1 through 85) was assessed at Weeks 1, 2, 4, 6, 8, 10, and 12; baseline was Day 1.

  2. Fluorescein Nasal Region Score (0 = None - 4 = Severe)

    Change from baseline comparison of reproxalap to vehicle for fluorescein staining of the nasal region (0 = none - 4 = severe), where a higher score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline calculated using baseline fluorescein nasal score, treatment arm, visit, and the interaction of treatment arm and visit as fixed effects.

    Time frame: The efficacy assessment period (Day 15 through 85) was assessed at Weeks 2, 4, 6, 8, 10, and 12; baseline was Day 1.

07

Results

Posted Jan 23, 2025

Participant flow

Participant flow — Overall Study
MilestoneReproxalap Ophthalmic Solution (0.25%) QIDVehicle Ophthalmic Solution QIDReproxalap Ophthalmic Solution (0.25%) QID to BIDVehicle Ophthalmic Solution QID to BID
Started105106105106
Completed9810294104
Not completed74112

Outcome measures

PrimarySubject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS))

Change from baseline comparison of reproxalap to vehicle for subject-reported ocular dryness score VAS (0 = no discomfort - 100 = maximal discomfort), where a higher score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline calculated using baseline score, treatment arm, visit, and the interaction of treatment arm and visit as fixed effects.

Time frame:
The efficacy assessment period (Day 1 through 85) was assessed at Weeks 1, 2, 4, 6, 8, 10, and 12; baseline was Day 1.
Reported as:
Least squares mean · score on a scale
Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS))
score on a scaleReproxalap Ophthalmic Solution (0.25%) QIDVehicle Ophthalmic Solution QIDReproxalap Ophthalmic Solution (0.25%) QID to BIDVehicle Ophthalmic Solution QID to BID
Subject-reported Ocular Dryness Score (0 - 100 Visual Analogue Scale (VAS))-11.5 ± 2.44-15.0 ± 2.39-17.8 ± 2.20-6.8 ± 2.12
PrimaryFluorescein Nasal Region Score (0 = None - 4 = Severe)

Change from baseline comparison of reproxalap to vehicle for fluorescein staining of the nasal region (0 = none - 4 = severe), where a higher score means a worse outcome. The intervention was administered bilaterally. The least squares mean (standard error) was derived from mixed model repeated measures for change from baseline calculated using baseline fluorescein nasal score, treatment arm, visit, and the interaction of treatment arm and visit as fixed effects.

Time frame:
The efficacy assessment period (Day 15 through 85) was assessed at Weeks 2, 4, 6, 8, 10, and 12; baseline was Day 1.
Reported as:
Least squares mean · units on a scale
Fluorescein Nasal Region Score (0 = None - 4 = Severe)
units on a scaleReproxalap Ophthalmic Solution (0.25%) QIDVehicle Ophthalmic Solution QIDReproxalap Ophthalmic Solution (0.25%) QID to BIDVehicle Ophthalmic Solution QID to BID
Fluorescein Nasal Region Score (0 = None - 4 = Severe)-0.47 ± 0.060-0.46 ± 0.058-0.53 ± 0.056-0.46 ± 0.053

Adverse events

Collected over The period of time over which adverse events were collected for each subject in the clinical trial was approximately three months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reproxalap Ophthalmic Solution (0.25%) QID0/105 (0%)3/105 (2.9%)88/105 (83.8%)
Vehicle Ophthalmic Solution QID0/106 (0%)3/106 (2.8%)7/106 (6.6%)
Reproxalap Ophthalmic Solution (0.25%) QID to BID0/105 (0%)1/105 (1%)94/105 (89.5%)
Vehicle Ophthalmic Solution QID to BID0/106 (0%)2/106 (1.9%)1/106 (0.9%)
Most frequent serious events
Most frequent serious events
EventReproxalap Ophthalmic Solution (0.25%) QIDVehicle Ophthalmic Solution QIDReproxalap Ophthalmic Solution (0.25%) QID to BIDVehicle Ophthalmic Solution QID to BID
Acute kidney injuryRenal and urinary disorders0/1050/1061/1050/106
Gastroenteritis salmonellaInfections and infestations1/1050/1060/1050/106
HypoxiaRespiratory, thoracic and mediastinal disorders1/1050/1060/1050/106
PneumoniaInfections and infestations1/1050/1060/1050/106
Spinal compression fractureInjury, poisoning and procedural complications0/1050/1060/1051/106
Peripheral arterial occlusive diseaseVascular disorders0/1051/1060/1050/106
Cerebrovascular accidentNervous system disorders0/1050/1060/1051/106
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/1051/1060/1050/106
OsteomyelitisInfections and infestations0/1051/1060/1050/106
Most frequent other events
Most frequent other events
EventReproxalap Ophthalmic Solution (0.25%) QIDVehicle Ophthalmic Solution QIDReproxalap Ophthalmic Solution (0.25%) QID to BIDVehicle Ophthalmic Solution QID to BID
General disorders and administration site conditionsGeneral disorders88/1057/10694/1051/106

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Reproxalap Ophthalmic Solution (0.25%) QIDVehicle Ophthalmic Solution QIDReproxalap Ophthalmic Solution (0.25%) QID to BIDVehicle Ophthalmic Solution QID to BIDTotal
<=18 years00000
Between 18 and 65 years40504349182
>=65 years65566257240
Sex: Female, Male
Sex: Female, Male(Participants)Reproxalap Ophthalmic Solution (0.25%) QIDVehicle Ophthalmic Solution QIDReproxalap Ophthalmic Solution (0.25%) QID to BIDVehicle Ophthalmic Solution QID to BIDTotal
Female78777582312
Male27293024110
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Reproxalap Ophthalmic Solution (0.25%) QIDVehicle Ophthalmic Solution QIDReproxalap Ophthalmic Solution (0.25%) QID to BIDVehicle Ophthalmic Solution QID to BIDTotal
Hispanic or Latino988833
Not Hispanic or Latino96989798389
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Reproxalap Ophthalmic Solution (0.25%) QIDVehicle Ophthalmic Solution QIDReproxalap Ophthalmic Solution (0.25%) QID to BIDVehicle Ophthalmic Solution QID to BIDTotal
American Indian or Alaska Native03003
Asian448925
Black or African American776727
Native Hawaiian or Other Pacific Islander01001
White92919090363
Multiple10001
Other10102
Region of Enrollment
Region of Enrollment(Participants)Reproxalap Ophthalmic Solution (0.25%) QIDVehicle Ophthalmic Solution QIDReproxalap Ophthalmic Solution (0.25%) QID to BIDVehicle Ophthalmic Solution QID to BIDTotal
United States105106105106422
Iris Color (Right Eye)
Iris Color (Right Eye)(Participants)Reproxalap Ophthalmic Solution (0.25%) QIDVehicle Ophthalmic Solution QIDReproxalap Ophthalmic Solution (0.25%) QID to BIDVehicle Ophthalmic Solution QID to BIDTotal
Black11013
Blue32383426130
Brown41374453175
Hazel1820131263
Gray10023
Green1210141248
Other00000
Iris Color (Left Eye)
Iris Color (Left Eye)(Participants)Reproxalap Ophthalmic Solution (0.25%) QIDVehicle Ophthalmic Solution QIDReproxalap Ophthalmic Solution (0.25%) QID to BIDVehicle Ophthalmic Solution QID to BIDTotal
Black11013
Blue32383426130
Brown41374453175
Hazel1820131263
Gray10023
Green1210141248
Other00000
08

Study locations

1 site
  • Eye Research Foundation
    Newport Beach, California 92663, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Oct 2019, 5 months.

Results were first posted in Jan 2025, 5 years 3 months after primary completion. A results delay was requested in Dec 2020.

Of 81 industry-sponsored phase 3 interventional studies under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 15. This study's 5 months is below that.

Counting every sponsor, half of 96 studies reached it within 10 months; a quarter within 7 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 15, 2019
First posted
Mar 19, 2019
StartActual
Apr 16, 2019
Primary completionActual
Oct 4, 2019
CompletionActual
Oct 4, 2019
Results delay requested
Dec 2, 2020
Results first posted
Jan 23, 2025
Last update
Jan 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03879863
Responsible party
Sponsor
First posted
Mar 19, 2019
Start date
Apr 16, 2019
Primary completion
Oct 4, 2019
Completion
Oct 4, 2019
Results posted
Jan 23, 2025
Last update
Jan 23, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion